Abstract
The radiochromic dosimeter PRESAGE® has shown potential in conventional radiotherapies, but it suffers from dose under-responding, or signal quenching, in proton therapy as a result of dependence on variations in the linear energy transfer (LET). Early investigations have shown the under-response is affected by the chemical concentration of the active components, but as yet this relationship has not been comprehensively measured. This study investigated the impact of PRESAGE® formulation changes on signal quenching to determine the magnitude by which the quenching can be minimized.